Is China A Black Swan For Big Pharma? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Spend a week in Shanghai these days and you hear a lot about how the Big Pharma model is broken. China's life sciences leaders - many of whom are returnees from the U.S. - are talking about this openly, much like industry leaders now do in the U.S. The difference is that many executives on the ground here believe that China is evolving into a laboratory for doing things differently, a catalyst for disruptive innovation that may propel the pharma industry into changing how it develops and delivers drugs
You may also be interested in...
Is China A Black Swan For Big Pharma? (Part 2 of 2)
[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]
Is China A Black Swan For Big Pharma? (Part 2 of 2)
[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]
Regulatory Revisions, Cut Backs At Big Pharma, Provide Spark For China Innovation - BayHelix Annual Meeting
SHANGHAI - BayHelix, a leading life sciences professional society for business leaders of Chinese origin, held its eighth annual conference in Shanghai April 10, and the day-long symposium trumpeted the opportunities for domestic pharma innovation brought on by China's healthcare reform and regulatory enhancements